Difference between revisions of "Dacomitinib (Vizimpro)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
|||
| Line 16: | Line 16: | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | + | ||
[[Category:EGFR inhibitors]] | [[Category:EGFR inhibitors]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
Revision as of 23:06, 28 February 2020
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells.
Diseases for which it is approved
History of changes in FDA indication
- 9/27/2018: Initial approval for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.
Also known as
- Code name: PF-00299804
- Brand name: Vizimpro